http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101259239-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1214 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2009-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101259239-B1 |
| titleOfInvention | Antibodies to PCL |
| abstract | The present invention provides an effective means for the treatment of an infection, in particular infection by Pseudomonas aeruginosa. Provided are a monoclonal antibody or part thereof against PcrV, and a pharmaceutical composition comprising these as an active ingredient. Specifically, the monoclonal antibody of the present invention is excellent in inhibiting cytotoxic activity against target cells of Pseudomonas aeruginosa. In addition, the monoclonal antibodies of the invention have high affinity for PcrV. |
| priorityDate | 2008-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 487.